BR112014017968A8 - Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos - Google Patents

Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos

Info

Publication number
BR112014017968A8
BR112014017968A8 BR112014017968A BR112014017968A BR112014017968A8 BR 112014017968 A8 BR112014017968 A8 BR 112014017968A8 BR 112014017968 A BR112014017968 A BR 112014017968A BR 112014017968 A BR112014017968 A BR 112014017968A BR 112014017968 A8 BR112014017968 A8 BR 112014017968A8
Authority
BR
Brazil
Prior art keywords
preparation
lactam compounds
antibacterial agents
substituted beta
amidine
Prior art date
Application number
BR112014017968A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014017968A2 (OSRAM
Inventor
Schiffer Guido
Klenke Burkhard
Wiegand Irith
Broetz-Oester-Helt Heike
N Maiti Samarendra
Khan Jehangir
Reddy Andhe
Yang Zhixiang
Hena Mostafa
Jia Guofeng
Ligong Ou
Liang Hong
Yip Judy
Gao Chuanjun
Tajammul Sabiha
Mohammad Rahim
Biswajeet Ganguli
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of BR112014017968A2 publication Critical patent/BR112014017968A2/pt
Publication of BR112014017968A8 publication Critical patent/BR112014017968A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112014017968A 2012-01-24 2013-01-23 Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos BR112014017968A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (2)

Publication Number Publication Date
BR112014017968A2 BR112014017968A2 (OSRAM) 2017-06-20
BR112014017968A8 true BR112014017968A8 (pt) 2017-07-11

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017968A BR112014017968A8 (pt) 2012-01-24 2013-01-23 Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos

Country Status (42)

Country Link
US (2) US9556165B2 (OSRAM)
EP (1) EP2806873B1 (OSRAM)
JP (1) JP5869701B2 (OSRAM)
KR (1) KR102036393B1 (OSRAM)
CN (1) CN104203237A (OSRAM)
AP (1) AP2014007880A0 (OSRAM)
AR (1) AR089796A1 (OSRAM)
AU (1) AU2013211575B2 (OSRAM)
BR (1) BR112014017968A8 (OSRAM)
CA (1) CA2862338C (OSRAM)
CL (1) CL2014001956A1 (OSRAM)
CO (1) CO7101240A2 (OSRAM)
CU (1) CU24273B1 (OSRAM)
CY (1) CY1117955T1 (OSRAM)
DK (1) DK2806873T3 (OSRAM)
EA (1) EA027126B1 (OSRAM)
EC (1) ECSP14010249A (OSRAM)
ES (1) ES2592403T3 (OSRAM)
HR (1) HRP20161171T1 (OSRAM)
HU (1) HUE030452T2 (OSRAM)
IL (1) IL233805A (OSRAM)
IN (1) IN2014MN01640A (OSRAM)
LT (1) LT2806873T (OSRAM)
MA (1) MA35905B1 (OSRAM)
ME (1) ME02532B (OSRAM)
MX (1) MX346602B (OSRAM)
MY (1) MY173843A (OSRAM)
NZ (1) NZ626951A (OSRAM)
PE (1) PE20142345A1 (OSRAM)
PH (1) PH12014501671B1 (OSRAM)
PL (1) PL2806873T3 (OSRAM)
PT (1) PT2806873T (OSRAM)
RS (1) RS55210B1 (OSRAM)
SG (1) SG11201403930XA (OSRAM)
SI (1) SI2806873T1 (OSRAM)
SM (1) SMT201600354B (OSRAM)
TN (1) TN2014000297A1 (OSRAM)
TW (1) TWI659953B (OSRAM)
UA (1) UA110880C2 (OSRAM)
UY (1) UY34585A (OSRAM)
WO (1) WO2013110643A1 (OSRAM)
ZA (1) ZA201405057B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160326157A1 (en) * 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
RS58509B1 (sr) 2014-03-24 2019-04-30 Novartis Ag Organska jedinjenja monobaktama za lečenje bakterijskih infekcija
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
RU2754180C2 (ru) 2015-09-23 2021-08-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
MX385731B (es) 2015-12-15 2025-03-18 Merck Sharp & Dohme Llc Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
MX2018010878A (es) * 2016-03-07 2018-11-09 Merck Sharp & Dohme Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
IL264686B2 (en) 2016-08-26 2024-07-01 Codexis Inc Engineered imine reductases and methods for reversible amination of ketone and amine compounds
WO2018091671A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
JP2019535722A (ja) 2016-11-18 2019-12-12 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾シクロデキストリン及び酸性化剤に基づくアミジン置換ベータ−ラクタム化合物の新規製剤、それらの製造及び抗菌医薬組成物としての使用
KR20190092566A (ko) * 2016-12-21 2019-08-07 아이쿠리스 게엠베하 운트 코. 카게 항생제 내성 박테리아 균주에 의한 감염을 위한 아미딘 치환된 β-락탐 화합물 및 β-락타마제 억제제를 사용하는 조합 요법
CA3070010A1 (en) 2017-07-18 2019-01-24 Bayer Cropscience Aktiengesellschaft Substituted 3-heteroaryloxy-1h-pyrazoles and salts thereof and their use as herbicidal active substances
TW201920163A (zh) 2017-07-28 2019-06-01 德商艾庫里斯抗感染治療有限公司 (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型
AU2018311521B2 (en) 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
BR112020006594A2 (pt) * 2017-10-02 2020-12-15 Arixa Pharmaceuticals, Inc. Derivados de aztreonam e usos dos mesmos
AU2018345523B2 (en) * 2017-10-02 2021-10-21 Merck Sharp & Dohme Llc Chromane monobactam compounds for the treatment of bacterial infections
WO2019144969A1 (zh) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
CN112771040B (zh) * 2018-11-13 2022-10-18 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
JP7179185B2 (ja) 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β-ラクタム化合物の使用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
CN114728953B (zh) * 2020-08-06 2024-04-09 宁夏农林科学院 β-内酰胺类化合物,及其制备方法以及其作为抗菌素的应用
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
US11932637B2 (en) 2021-11-18 2024-03-19 Merck Sharp & Dohme Llc Chromane amidine monobactam compounds for the treatment of bacterial infections
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
JPH01290674A (ja) 1988-04-04 1989-11-22 E R Squibb & Sons Inc アゼチジニル誘導体
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
IL154593A0 (en) 2000-09-14 2003-09-17 Pantherix Ltd 3-(heteroaryl acetamido)-2-oxoazetidine-1-sulfonic acid derivatives as antibacterial agents
CN1914151A (zh) 2004-01-27 2007-02-14 默克弗罗斯特公司 作为环氧合酶-2抑制剂的二芳基-2(5h)-呋喃酮类的释放一氧化氮的前药
CN101511187B (zh) 2005-09-23 2012-07-04 株式会社爱慕知科学 哌啶和哌嗪衍生物
US8901293B2 (en) 2005-12-07 2014-12-02 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
RU2451677C2 (ru) 2006-02-14 2012-05-27 Ихара Кемикал Индастри Ко., Лтд. Способ получения соединения 5-алкокси-4-гидроксиметилпиразола
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
AU2008231854B2 (en) * 2007-03-23 2013-03-21 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
KR20110086742A (ko) 2008-12-19 2011-07-29 화이자 인코포레이티드 모노카밤

Also Published As

Publication number Publication date
IN2014MN01640A (OSRAM) 2015-05-22
ES2592403T3 (es) 2016-11-30
EA201400838A1 (ru) 2014-12-30
BR112014017968A2 (OSRAM) 2017-06-20
EP2806873B1 (en) 2016-06-15
PH12014501671A1 (en) 2014-11-10
EA027126B1 (ru) 2017-06-30
HRP20161171T1 (hr) 2016-11-04
SG11201403930XA (en) 2014-08-28
PL2806873T3 (pl) 2016-12-30
CL2014001956A1 (es) 2014-11-07
US20150045340A1 (en) 2015-02-12
CY1117955T1 (el) 2017-05-17
AP2014007880A0 (en) 2014-08-31
PH12014501671B1 (en) 2020-02-28
ECSP14010249A (es) 2015-12-31
US9782390B2 (en) 2017-10-10
HK1203389A1 (zh) 2015-10-30
NZ626951A (en) 2016-03-31
LT2806873T (lt) 2016-10-10
KR102036393B1 (ko) 2019-10-24
UA110880C2 (uk) 2016-02-25
JP5869701B2 (ja) 2016-02-24
EP2806873A1 (en) 2014-12-03
MX346602B (es) 2017-03-24
TN2014000297A1 (en) 2015-12-21
HUE030452T2 (en) 2017-05-29
MY173843A (en) 2020-02-24
CU20140090A7 (es) 2014-12-26
AU2013211575A1 (en) 2014-07-24
US20170100379A1 (en) 2017-04-13
US9556165B2 (en) 2017-01-31
CA2862338A1 (en) 2013-08-01
MA35905B1 (fr) 2014-12-01
WO2013110643A1 (en) 2013-08-01
SMT201600354B (it) 2016-11-10
TW201343643A (zh) 2013-11-01
MX2014008915A (es) 2014-08-26
AR089796A1 (es) 2014-09-17
CO7101240A2 (es) 2014-10-31
CA2862338C (en) 2019-04-16
CU24273B1 (es) 2017-08-08
RS55210B1 (sr) 2017-01-31
PT2806873T (pt) 2016-09-23
KR20140114390A (ko) 2014-09-26
CN104203237A (zh) 2014-12-10
IL233805A (en) 2016-06-30
JP2015504907A (ja) 2015-02-16
TWI659953B (zh) 2019-05-21
ME02532B (me) 2017-02-20
IL233805A0 (en) 2014-09-30
SI2806873T1 (sl) 2016-10-28
AU2013211575B2 (en) 2017-03-02
PE20142345A1 (es) 2015-01-09
UY34585A (es) 2013-09-02
DK2806873T3 (en) 2016-08-29
ZA201405057B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
BR112014017968A8 (pt) Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos
BRPI0907435A8 (pt) derivados de 5-flúor pirimidina
BR112012027439A2 (pt) derivados de n1-sulfonil-5-flúor-pirimidinona n3-substituídos
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
BR112014003216A2 (pt) compostos, processos para preparação de compostos de fórmula i, composições agroquímicas, uso de compostos de fórmula i ou viii e uso de pelo menos um composto de fórmula i ou viii
BR112014003587A2 (pt) derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112014004310A2 (pt) composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112015006868A2 (pt) composições antibióticas de tazobactam arginina
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
IN2014MN02484A (OSRAM)
BR112019000988A2 (pt) derivado de triazolopirazinona útil como inibidor de pde1 humana
BR112015010570A2 (pt) agentes antimicrobianos
CY1116238T1 (el) Ενωσεις me αντιβακτηριακη δραστικοτητα εναντι clostridium
CO6382113A2 (es) Compuestos quimicos
BR112015026516A2 (pt) agentes antibacterianos de fenicol inovadores
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
WO2014101294A9 (zh) 糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
TH157415A (th) สารประกอบแอมิดีน ซับสทิทิวเทดเบต้า-แลคแทม, การเตรียมสารเหล่านี้และการใช้สารเหล่านี้เป็นสารฆ่าแบคทีเรีย

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements